Immatics Biotechnologies has been granted a patent for peptides, proteins, nucleic acids, and cells for cancer immunotherapy. The patent includes a specific peptide sequence FVDNQYWRY (SEQ ID NO: 115) as a potential pharmaceutical ingredient in the form of a salt. GlobalData’s report on Immatics Biotechnologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Immatics Biotechnologies GmbH - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Immatics Biotechnologies, was a key innovation area identified from patents.

Peptide fvdnqywry for immunotherapy of cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Immatics Biotechnologies GmbH

A recently granted patent (Publication Number: US11919940B2) discloses a peptide with the amino acid sequence FVDNQYWRY (SEQ ID NO: 115) in the form of a pharmaceutically acceptable salt. This peptide has been identified to have the ability to bind to an MHC class-I molecule and can be recognized by CD8 T cells when bound to the MHC. The patent also covers compositions containing this peptide along with a pharmaceutically acceptable carrier, with options for the peptide to be in the form of chloride salt or acetate salt.

Furthermore, the patent includes compositions with the peptide along with various adjuvants like anti-CD40 antibody, interleukins, interferons, and other immune-modulating agents. Additionally, a pegylated version of the peptide is also disclosed in the patent, along with methods of production using solid-phase peptide synthesis or expression systems in yeast or bacterial cells. The compositions described in the patent are intended for use as pharmaceutical compositions, including water and a buffer, highlighting the potential therapeutic applications of the peptide in various medical contexts.

To know more about GlobalData’s detailed insights on Immatics Biotechnologies, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies